Sarepta Therapeutics Inc
(LTS:0L35)
$
121.67
0 (0%)
Market Cap: 11.61 Bil
Enterprise Value: 11.80 Bil
PE Ratio: 78.90
PB Ratio: 9.50
GF Score: 82/100 Sarepta Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022 / 07:15PM GMT
Release Date Price:
$121.9
(+3.31%)
Gavin Clark;Gartner
Evercore ISI Institutional Equities, Research Division - Analyst
All right. Welcome, everyone. This is Gavin Clark-Gartner from the Evercore ISI Biotech Research team, and I'm very happy to be here with Doug Ingram, the President and CEO of Sarepta Therapeutics. Doug, thanks for joining us.
Questions & Answers
Gavin Clark;Gartner
Evercore ISI Institutional Equities, Research Division - Analyst
Only have 20 minutes for this fireside, so we're going to dive straight into the Q&A. Your first question, focusing on 9001, micro-dystrophin gene therapy for LGMD, starting on the regulatory and clinical aspects, especially with the Study 102, with the initial cohort that was underdosed, have you done any post-hoc analyses to correlate micro-dystrophin expression to functional benefit?
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director
We have done a number of analytics. So first of all, we've done a number of analytics to look
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot